Runben Biotechnology (SH:603193) NORTHEAST SECURITIES·2025-08-20 08:35Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company experienced a slowdown in performance in the first half of 2025, with a revenue of 895 million yuan, representing a year-on-year increase of 20.31%, and a net profit of 188 million yuan, up by 4.16% [1]. - The second quarter of 2025 saw a revenue of 655 million yuan, an increase of 13.46%, but a decline in net profit to 143 million yuan, down by 0.85% [2]. - The company plans to focus on its infant care segment in the second half of the year to drive performance [2]. Financial Performance Summary - In the first half of 2025, the company reported a gross margin of 58.01%, down by 0.63 percentage points, and a net profit margin of 20.95%, down by 3.25 percentage points [3]. - The sales expense ratio increased to 30.25% in the first half of 2025, up by 1.52 percentage points, due to increased marketing efforts on platforms like Douyin [3]. - The company expects revenues for 2025 to reach 1.62 billion yuan, with net profits projected at 339 million yuan, reflecting a growth rate of 13.01% [5]. Product Performance Breakdown - The revenue from mosquito repellent products was 332 million yuan, up by 13.83%, accounting for 50.65% of total revenue [2]. - Infant care products generated 226 million yuan, a 22.89% increase, representing 34.45% of total revenue, driven by higher-priced new products [2]. - Essential oil revenue decreased by 15.64% to 81 million yuan, accounting for 12.37% of total revenue, attributed to changes in product sales structure [2]. Future Outlook - The company anticipates continued growth in market share due to its strong brand image, product innovation, and operational capabilities [4]. - Revenue projections for 2025-2027 are set at 1.62 billion yuan, 1.99 billion yuan, and 2.45 billion yuan, respectively, with corresponding net profits of 339 million yuan, 419 million yuan, and 516 million yuan [4].